26295
The agent is in phase III clinical development for the treatment of myelofibrosis and in phase II development for systemic sclerosis .
 None
Please list all entity words in the text that fit the category. Output format is "word1, word2". 
Option: Chemical 
Text: {0} 
Answer:
 None